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Abstract
Introduction Three-dimensional rotational angiography
(3DRA) has been used in the guidance of various trans-
catheter therapies including percutaneous pulmonary valve
implantation (PPVI). The most recently available 3D
image fusion software (VesselNavigator, Philips) extends
this technology to use pre-registered computed tomography
or magnetic resonance imaging datasets, promising reduc-
tions in contrast and radiation exposure along with shorter
procedural times.
Methods In this retrospective review, patients were as-
signed to three groups according to the mode of imaging
guidance: two-dimensional angiography (2DA), 3DRA and
VesselNavigator (VN) assisted valve implantation. Patient
characteristics and catheterisation data were reviewed with
a focus on contrast and radiation exposure, fluoroscopy, and
procedural times.
Results Between July 2012 and June 2016, 21 patients un-
derwent PPVI: 8 with 2D guidance, 6 patients with 3DRA
and most recently 7 patients with VN assistance. Patents
in the VN group received significantly less absolute and
weight indexed contrast when compared with those with
2DA or 3DRA guided PPVI. Patients in the 2DA group
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received a significantly higher total dose area product radi-
ation dose and air kerma in comparison with patients with
3DRA and VN guided intervention. Application of VN
resulted in the shortest fluoroscopy time, although not sta-
tistically significant, and a significantly shorter study time
when compared with 2DA.
Conclusions Utilisation of pre-intervention image manip-
ulation with VesselNavigator for 3D guidance of PPVI re-
sults in a reduction in contrast and radiation exposure and
study time as compared with traditional 2D guidance, and
contrast usage as compared with 3DRA.
Keywords PPVI · 3DRA · 3D guidance · VesselNavigator
Introduction
Over the last 15 years, percutaneous pulmonary valve im-
plantation (PPVI) has become an effective and less invasive
alternative to surgical right ventricle-to-pulmonary artery
conduit replacement [1–3]. Promising early and mid-term
outcomes have stimulated the search for new devices and
techniques to offer this treatment to a wider patient pop-
ulation [4, 5]. Potential complications linked to this ther-
apy, such as coronary artery compression, graft rupture or
stent fracture, have required modifications of implantation
protocols [6–8]. Despite non-invasive three-dimensional
(3D) imaging being routinely performed in qualification and
planning of PPVI, traditional two-dimensional (2D) imag-
ing remains the mainstay for intervention guidance [1–8].
The development of fusion imaging software has led to
the introduction of three-dimensional rotational angiogra-
phy (3DRA) for the guidance of various transcatheter ther-
apies, including PPVI [9–12]. The most recently available
3D image fusion software (VesselNavigator, Philips), which
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Fig. 1 VesselNavigator assisted percutaneous pulmonary valve implantation. Automatic three-dimensional (3D) reconstruction (a, left panel) and
row scans (right panels) from pre-registered computed tomography were manipulated to outline the conduit and the proximal pulmonary arteries
(b). In addition to bony structures, heavy conduit calcifications were utilised to enhance manual 3D image fusion with live fluoroscopy (c). The
3D roadmap was utilised to guide creation of the landing zone (d) and subsequent implantation (e, f) of a Melody valve (Medtronic Inc.)
uses pre-registered computed tomography (CT) or magnetic
resonance imaging (MRI) datasets, promises further reduc-
tions in contrast and radiation exposure along with shorter
procedural times [13–15]. In this report we sought to de-
scribe our experience with three imaging modalities for
guidance of PPVI.
Methods
We performed a retrospective review of all percutaneous
pulmonary valve implantations at the Polish Mother’s
Memorial Hospital. Patients were assigned to three groups
according to the mode of imaging guidance: two-dimen-
sional angiography (2DA), 3DRA (Phillips Allura XPER
FD20) and VesselNavigator (VN) assisted valve implanta-
tion. Patient characteristics and catheterisation data were
reviewed with a focus on contrast and radiation exposure,
fluoroscopy, and procedural times. For detailed compari-
son total contrast volume, dose area product, air kerma and
fluoroscopy time were indexed to body weight.
Procedural description
The majority of patients (19/21) had a contrast chest CT
prior to discussion and qualification for PPVI on multidis-
ciplinary meeting. The procedures were conducted under
general anaesthesia, complying with the usual catheter-
isation techniques and standard PPVI protocol. 3DRA
has been available at our institution since 2010, before
commencement of the Melody valve implantation program.
VesselNavigator was introduced in September 2015. Se-
lection of imaging guidance was at the discretion of the
operator.
3DRA
3DRA was performed with the following settings: a fully
automated 4.1 s, 240˚ C-arm rotation from 120˚ right an-
terior oblique to 120˚ left anterior oblique with acquisi-
tion of 30 frames per second. To limit motion artefact the
study was performed during an expiratory breath-hold. Ini-
tially we used full strength contrast and in the most recent
patients we injected dilute contrast at a concentration of
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tion and C-arm rotation was set at 1 s. Manipulation to limit
cardiac output during acquisition was not performed.
An unprocessed rotational dataset was manipulated
on a dedicated workstation (Interventional Tools, Philips
Healthcare) by the same operator for all patients. The re-
constructed images were optimised by manual windowing
and segmentation. The volume rendered 3D reconstruction
was merged with live fluoroscopic images using the auto-
mated software for guidance of stent and valve positioning
and implantation.
VesselNavigator
Application of VesselNavigator is based on four steps: seg-
mentation, planning, registration and live guidance (Fig. 1;
[13, 14]). In the first step, the application automatically
creates a volume rendered 3D reconstruction from a raw
CT or MRI dataset. Next, manual segmentation is per-
formed by highlighting and selecting the desired region of
interest on the 3D reconstruction or orthogonal MPRs. The
second stage enables planning of the procedure by placing
marking rings/points, taking measurements and selecting
and storing the best angulations for the attempted interven-
tion. The third stage includes fusion of live fluoroscopy
and the manipulated 3D reconstruction. After storing fluo-
roscopy images in two, min 30° separated projections, ves-
sel borders visualised with injection of a small amount of
contrast medium or internal markers such as bony struc-
tures, shadow of the heart and great vessels, calcifications
or previously implanted devices, serve as reference points
for fusion. Finally live guidance of the procedure is per-
formed with 3D roadmap overlaid and presented in several
rendering modes with or without marking rings/points.
Statistical analysis
Data analysis was performed using GraphPad InStat soft-
ware (GraphPad Software, Inc., San Diego, CA, USA).
Data are presented as frequency with percentage of the
total, median with range, or mean ± standard deviation,
as appropriate. Student’s t-test or a Mann-Whitney test,
where indicated, was used for analysis. The level of statis-
tical significance was set at p  0.05.
Results
Between July 2012 and June 2016, 21 patients underwent
PPVI: 8 with 2DA guidance, 6 patients with 3DRA and
most recently 7 patients with VN assistance. Table 1
summarises patients clinical and procedural characteristics.
Comparison of demographic data showed no difference
between the three groups (Table 2). There were no signif-
icant differences in the number of previous interventions,
pulmonary stenosis gradient, number of implanted stents,
and repeat dilation after implantation.
VN patients received the lowest contrast dose (1.5 ml/kg,
1.1–3.6), significantly less than those with 3DRA (4.7 ml/kg,
1.5–6.3; p < 0.05) or 2DA guidance (3.8 ml/kg, 1.0–10.7;
p < 0.05) (Table 3; Fig. 2). There was no significant differ-
ence in absolute or weight adjusted contrast usage between
2D and 3DRA guided PPVI.
Two-dimensional guidance resulted in significantly
higher dose area product (DAP) (17,745.9 cGycm2,
13,411.2–24,808.5) compared with 3DRA (10,832.3 cGycm2,
5961.2–15,265.9; p < 0.05) or VN (6498.1 cGycm2,
15,07.0–16,694.1; p < 0.05) assisted intervention. When
adjusted to body weight, the 2DA group received the high-
est DAP (475.9 cGycm2/kg, 243.8–632.6) compared with
3DRA (208.3 cGycm2/kg, 132.5–321.4; p < 0.05) or VN
(159.1 cGycm2/kg, 48.6–298.1; p < 0.05). The VN group
received lower absolute and weight adjusted DAP com-
pared with the 3DRA group; however, the differences were
not statistically significant.
Patients in the 2DA group received significantly higher
total and air kerma (1191 mGy, 900.1–1665), in comparison
to those with 3DRA (727 mGy, 400.1–1024.6; p < 0.05) or
VN (450 mGy, 122–1293; p < 0.05). When adjusted to pa-
tient weight, the 2DA group (31.9 mGy/kg, 16.4–42.5) was
exposed to significantly higher air kerma when compared
with 3DRA (14 mGy/kg, 8.9–21.6; p < 0.05) or VN group
(10.1 mGy/kg, 3.9–23.1; p < 0.05).
Table 1 Clinical and procedural characteristics of all patients treated
with PPVI
Total (21)
Age (years) 13.8 (7.8–19.6)
Weight (kg) 46 (28–98)
BSA (m2) 1.5 (1.0–2.2)
Diagnosis
Truncus arteriosus 8 (40%)
Tetralogy of Fallot 5 (25%)
Aortic stenosis 5 (25%)
Other 2 (10%)
Number of previous RVOT intervention 9 (45%)
Pulmonary stenosis gradient (mm Hg) 32 (6–100)
Number of stents placed 27 (1–3)
Post-dilation 7 (35%)
Ensemble size
18 mm 2 (10%)
20 mm 10 (50%)
22 mm 8 (40%)
PPVI percutaneous pulmonary valve implantation, BSA body surface
area, RVOT right ventricle outflow tract
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Table 2 Comparison of selected demographic and clinical data of PPVI guided with 2DA, 3DRA and VN
Total (n = 21) 2DA (n = 8) 3DRA (n = 6) VN (7) P
Age (years) 13.8 (7.8–19.6) 14 (9.7–19.6) 13.8 (12.3–17.6) 11.2 (7.8–16.1) 2D vs 3DRA, p = 0.89
2D vs VN, p = 0.29
3DRA vs VN, p = 0.19
Weight (kg) 46 (28–98) 53.5 (28–98) 49.3 (42.8–52.0) 40 (29–56) 2D vs 3DRA, p = 0.65
2D vs VN, p = 0.20
3DRA vs VN, p = 0.07
BSA (m2) 1.5 (1.0–2.2) 1.7 (1.0–2.2) 1.5 (1.4–1.6) 1.2 (1.1–1.6) 2D vs 3DRA, p = 0.59
2D vs VN, p = 0.07
3DRA vs VN, p = 0.06
PS gradient
(mm Hg)
32 (6–100) 34.5 (12–51) 25 (6–75) 41 (20–100) 2D vs 3DRA, p = 0.99
2D vs VN, p = 0.28
3DRA vs VN, p = 0.40
Number of stents
placed
30 (1–3) 11 (1–2) 10 (1–3) 9 (1–2) 2D vs 3DRA, p = 0.43
2D vs VN, p = 0.73
3DRA vs VN, p = 0.32
Post-dilation 7 (35%) 3 (37.5%) 1 (17%) 3 (43%) 2D vs 3DRA, p = 0.79
2D vs VN, p = 0.83
3DRA vs VN, p = 0.68
PPVI percutaneous pulmonary valve implantation, 2DA two-dimensional angiography, 3DRA three-dimensional rotational angiography, VN Ves-
selNavigator, BSA body surface area, PS pulmonary stenosis
Table 3 Comparison of contrast usage, radiation exposure, fluoroscopy and study times between PPVI performed with 2DA, 3DRA and VN
guidance
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2D vs VN, p < 0.001
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2D vs VN, p = 0.047
3DRA vs VN, p = 0.04
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2D vs VN, p < 0.01
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2D vs 3DRA, p = 0.86
2D vs VN, p = 0.21











2D vs 3DRA, p = 0.27
2D vs VN, p = 0.01
3DRA vs VN, p = 0.26
PPVI percutaneous pulmonary valve implantation, 2DA two-dimensional angiography, 3DRA three-dimensional rotational angiography, VN Ves-
selNavigator
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Fig. 2 Comparison of absolute (a) and weight adjusted (b) contrast usage, weight adjusted air kerma (c) and dose area product (d), fluoroscopy
(e) and study times (f) between two-dimensional angiography (2DA), three-dimensional rotational angiography (3DRA) and VesselNavigator (VN)
guided percutaneous pulmonary valve implantation
Application of VN resulted in the shortest fluoroscopy
time (23.2 min, 9.3–53.5) when compared with 3DRA
(37.4 min, 21.5–55.3) or 2DA (34.8 min, 29.5–51.5); how-
ever, the differences were not statistically significant. The
same observation was true for weight-fluoroscopy time.
Patients in the VN group had significantly shorter proce-
dural times (125 min, 90–175) when compared with those
in the 2DA group (190 min, 135–240; p < 0.05). VN pro-
cedural times also tended to be shorter than those in the
3DRA group (137 min, 110–215), but this difference was
not statistically significant.
Discussion
Three-dimensional imaging has become increasingly popu-
lar in the planning and guidance of cardiac catheterisations.
Until recently, 3DRA has been the most frequently used
tool to generate a volumetric dataset and reconstruct it to
a 3D roadmap that could be used for navigation [9–12].
It has been shown to provide superior vascular visualisa-
tion, including complex spatial relationships unavailable
with 2DA, and facilitate interventions in various congen-
ital and structural lesions. However, limited data are avail-
able on the use of 3DRA in PPVI and even less is reported
on pre-registered 3D images in this context. As non-inva-
sive imaging of the right ventricular outflow tract (RVOT),
pulmonary arteries and coronary arteries is part of the rou-
tine protocol for PPVI, it seems natural to re-produce the
previous dataset for 3D mapping during the intervention.
Advances in image fusion software allow direct 2D-3D reg-
istration of live fluoroscopy with rendered 3D imaging from
CT or MRI scans, promising a reduction in contrast and ra-
diation exposure along with shorter procedural times [14,
15].
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In this study, for the first time, we compared three imag-
ing modalities for guidance of PPVI. When compared with
traditional 2DA, VN assistance resulted in significantly
lower contrast utilisation, radiation exposure and total
study time with a tendency towards shorter fluoroscopy
time. Our data reinforce results described by Tacher et al.
for endovascular aneurysm repair guided with 2DA, 3DRA
and fusion software similar to VN but based on 3D-3D
registration [16]. More recently Stangenberg et al. reported
the first application of VN for aortic aneurysm repair.
They compared VN and 2DA guided standard endovascu-
lar repair, achieving superior radiation and contrast dose
parameters with VN [13]. We were not able to show a sta-
tistically significant reduction in fluoroscopy time, despite
recording the shortest minimum and median fluoroscopy
times in the VN group. This may have been due to an
uneven distribution of technically challenging cases, which
may have required prolonged fluoroscopy regardless of the
type of imaging.
Nguyen at al. analysed 81 PPVIs including 29 with
3DRA guidance [12]. They were able to show that 3DRA
does not increase radiation exposure, despite patients in
the 3DRA group having more additional interventions. Al-
though based on a smaller patient population, our experi-
ence concurs that 3DRA provided lower DAP and air kerma
compared with 2DA.
Haddad at al. performed comparison of radiation and
contrast exposure for 3DRA with customised low dose ra-
diation protocol and 2DA [11]. In the group of 100 control
matched interventions, including 18 PPVIs, they reported
similar total radiation and contrast doses. This reflects our
observation that although utilisation of a 3D roadmap limits
or even negates contrast injections during stent/valve posi-
tioning, it requires a relatively large contrast load to obtain
the initial dataset.
In the context of contrast utilisation, VN assistance re-
sulted in the lowest volumes used in the entire group. In
fact, already in our early experience, reliable 3D roadmaps
allowed us to avoid RVOT contrast injections prior to stent
implantation in the majority of VN guided valve implants.
Lower contrast usage was the only significant difference
between 3DRA guidance and VN guidance in our study.
Although not statistically significant, the VN group had
lower radiation exposure, fluoroscopy and procedural times
than 3DRA. We need to acknowledge, however, that in sev-
eral VN assisted interventions 3DRA was performed at the
end of the study to visualise the final outcome. This might
confound results of the comparison but limited population
size hindered powerful statistical analysis of the subgroups.
Both 3D techniques resulted in significant lower radiation
exposure as compared with traditional 2DA.
This manuscript represents early clinical experience with
a complex new technique. Our hope and expectation is that
as we move along the learning curve we will see a more
demonstrable difference in favour of VN fusion imaging
with respect to all the parameters examined in our study.
Limitations
This is a single-centre, non-randomised retrospective study.
Due to the limited patient population we did not analyse
subgroups of patients with previous pre-stenting, those with
multiple 3DRAs or with a combination of imaging tech-
niques. Although the 3D roadmaps were prepared by the
same operator, valve implantations were performed by three
operators with different experience. Air kerma and DAP
were used as a predictors of deterministic and stochastic
effects, respectively; however, we did not have the capabil-
ity to convert DAP into effective dose.
Conclusions
Integration of pre-intervention imaging using the Vessel-
Navigator for 3D guidance of PPVI results in a significant
reduction in contrast, radiation exposure and study time,
compared with traditional 2DA. VN assistance also led to
significantly lower contrast usage. The radiation exposure
tended to be lower than with 3DRA, but this difference
did not reach statistical significance. Our initial experience
provides a proof of concept. We require a large multi-
centre collaborative study to fully evaluate this technology.
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